Johnson & Johnson

The short interest moves in biotech and emerging pharmaceutical companies were mixed in the first two weeks of April. The number of shares sold short in Alexion Pharmaceuticals (NASDAQ: ALXN), Amgen (NASDAQ: AMGN), Biogen Idec (NASDAQ: BIIB), Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ: GILD...

The earnings crunch is on this week, with first-quarter results due from such iconic blue chips as Coca-Cola, General Electric, Google, Johnson & Johnson, McDonald's and Microsoft. Analysts expect to see year-over-year earnings growth from each of them, but earnings declines from Intel,...

The short interest in biotech and emerging pharmaceutical companies was mixed in the final two weeks of March. The number of shares sold short in Alexion Pharmaceuticals (NASDAQ: ALXN), Arena Pharmaceuticals (NASDAQ: ARNA), Illumina (NASDAQ: ILMN), Onyx Pharmaceuticals (NASDAQ: ONXX), Vertex...

Dow Jones Industrial Average companies Chevron (NYSE: CVX), Exxon Mobil (NYSE: XOM), IBM (NYSE: IBM) and Johnson & Johnson (NYSE: JNJ) are about due to boost their payouts, according to a report on CNBC. These blue chips have significant cash hoards, buy back shares and are doing well now, as...

The short interest in biotech and emerging pharmaceutical companies was mixed again in the first two weeks of March. The number of shares sold short in Arena Pharmaceuticals (NASDAQ: ARNA), Dendreon (NASDAQ: DNDN), Illumina (NASDAQ: ILMN) and VIVUS (NASDAQ: VVUS) grew somewhat between the...

On Wednesday, Spectrum Pharmaceuticals (NASDAQ: SPPI) dropped 37 percent after releasing its Q1 and full year revenue guidance. The company said it expects sales of its colorectal cancer drug, Fusilev, to total $80 to $90 million in 2013 compared to $204 million in 2012. Seem like a huge drop...

The short interest in biotech and emerging pharmaceutical companies was mixed again in the final two weeks of February. The number of shares sold short in Alexion Pharmaceuticals (NASDAQ: ALXN), Arena Pharmaceuticals (NASDAQ: ARNA), Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ: GILD), Onyx...

A recent Australian study points toward possible good news in the search for answers regarding Alzheimer’s disease. The Border Mail reports that Australians will be among the first to test new drugs hoped to ward off Alzheimer’s after researchers discovered that the illness takes decades to...

The short interest in biotech and emerging pharmaceutical companies was mixed again in the first two weeks of February. The number of shares sold short in Arena Pharmaceuticals (NASDAQ: ARNA), Illumina (NASDAQ: ILMN) and Vertex Pharmaceuticals (NASDAQ: VRTX) grew somewhat between the January 31...

The short interest in biotech and emerging pharmaceutical companies was mixed again in the latter two weeks of January. The number of shares sold short in Arena Pharmaceuticals (NASDAQ: ARNA), Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ: GILD), Vertex Pharmaceuticals (NASDAQ: VRTX) and VIVUS...

The short interest in biotech and emerging pharmaceutical companies was mixed again in the first two weeks of January. The number of shares sold short in Arena Pharmaceuticals (NASDAQ: ARNA), Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ: GILD), Onyx Pharmaceuticals (NASDAQ: ONXX) and Vertex...

The focus was on the big banks last week, with Goldman Sachs (NYSE: GS), J.P. Morgan (NYSE: JPM) and Morgan Stanley (NYSE: MS) reporting strong results, but Bank of America (NYSE: BAC) and Citigroup (NYSE: C) not so much. The spotlight is on tech earnings this week. Analysts anticipate lower per-...

The short interest in biotech and emerging pharmaceutical companies was mixed again in the first two weeks of December. The number of shares sold short in Amgen (NASDAQ: AMGN), Arena Pharmaceuticals (NASDAQ: ARNA), Dendreon (NASDAQ: DNDN) and Illumina (NASDAQ: ILMN) grew somewhat between the...

This weekend in Barron's online: the outlook for 2013 and the prospects for Johnson & Johnson, Hudson Bay, Tronox and South Korea. Cover Story "Outlook 2013" by Vito J. Racanelli. Ten strategists recently polled by Barron's expect more gains ahead next year. Even if no fiscal cliff deal is...

The short interest in biotech and emerging pharmaceutical companies was mixed again in the final two weeks of November. Shares sold short in Alexion Pharmaceuticals (NASDAQ: ALXN), Illumina (NASDAQ: ILMN) and Regeneron Pharmaceuticals (NASDAQ: REGN) grew somewhat between the November 15 and...